{"doc_id": "33893337", "type of study": "Therapy", "title": "", "abstract": "Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab.\nTocilizumab (TCZ) and Dexamethasone are used for the treatment of critically ill COVID-19 patients.\nWe compared the short-term survival of critically ill COVID-19 patients treated with either TCZ or Dexamethasone.\n109 critically ill COVID-19 patients randomly assigned to either TCZ therapy (46 patients) or pulse Dexamethasone therapy (63 patients).\nAge, sex, neutrophil/ lymphocyte ratio, D-dimer, ferritin level, and CT chest pattern were comparable between groups.\nKaplan-Meier survival analysis showed better survival in Dexamethasone group compared with TCZ (P\u2009=\u20090.002), patients didn't need vasopressor at admission (P\u2009<\u20090.0001), patients on non-invasive ventilation compared to patients on mechanical ventilation (P<0.0001\u2009), and in patients with ground glass pattern in CT chest (P<0.0001\u2009) compared with those who have consolidation.\nCox regression analysis showed that, TCZ therapy (HR\u2009=\u20092.162, 95% CI, 1.144-4.087, P\u2009<0.0001)\u00a0compared with Dexamethasone group, higher neutrophil/Lymphocyte ratio (HR\u2009=\u20092.40, CI, 1.351-4.185, P\u2009=\u20090.003), lower PaO2/FiO2, 2\u00a0days after treatment, (HR\u2009=\u20091.147, 95% CI, 1.002-1.624, P\u2009<\u20090.0001) independently predicted higher probability of mortality.\nDexamethasone showed better survival in severe COVID-19 compared to TCZ.\nConsidering the risk factors mentioned here is crucial when dealing with severe COVID-19 cases.\nClinical trial registration No clinicalTrials.gov: Nal protocol approved by Hospital Authorities, for data collection and for participation in CT04519385 (19/08/2020).\n", "Evidence Map": {"Enrollment": [{"term": "critically ill COVID-19 Egyptian", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 55}, {"term": "assisted ventilation", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 88}, {"term": "critically ill COVID-19", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 62}, {"term": "critically ill COVID-19", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 27}, {"term": "vasopressor at admission", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 157}, {"term": "ground glass pattern", "negation": "affirmed", "UMLS": {}, "start": 297, "end": 317}, {"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 55}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab .", "Evidence Elements": {"Participant": [{"term": "critically ill COVID-19 Egyptian", "negation": "affirmed", "UMLS": {}, "start": 23, "end": 55}, {"term": "assisted ventilation", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 88}], "Intervention": [{"term": "Dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 107, "end": 120}, {"term": "Tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 124, "end": 135}], "Outcome": [{"term": "Short term survival", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 19}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Tocilizumab ( TCZ ) and Dexamethasone are used for the treatment of critically ill COVID-19 patients .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "We compared the short-term survival of critically ill COVID-19 patients treated with either TCZ or Dexamethasone .", "Evidence Elements": {"Participant": [{"term": "critically ill COVID-19", "negation": "affirmed", "UMLS": {}, "start": 39, "end": 62}], "Intervention": [{"term": "TCZ", "negation": "affirmed", "UMLS": {}, "start": 92, "end": 95}, {"term": "Dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 99, "end": 112}], "Outcome": [{"term": "short-term survival", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 35}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "109 critically ill COVID-19 patients randomly assigned to either TCZ therapy ( 46 patients ) or pulse Dexamethasone therapy ( 63 patients ) .", "Evidence Elements": {"Participant": [{"term": "critically ill COVID-19", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 27}], "Intervention": [{"term": "TCZ therapy", "negation": "affirmed", "UMLS": {}, "start": 65, "end": 76}, {"term": "pulse Dexamethasone therapy", "negation": "affirmed", "UMLS": {}, "start": 96, "end": 123}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Age , sex , neutrophil / lymphocyte ratio , D-dimer , ferritin level , and CT chest pattern were comparable between groups .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Kaplan-Meier survival analysis showed better survival in Dexamethasone group compared with TCZ ( P = 0.002 ) , patients didn 't need vasopressor at admission ( P < 0.0001 ) , patients on non-invasive ventilation compared to patients on mechanical ventilation ( P < 0.0001 ) , and in patients with ground glass pattern in CT chest ( P < 0.0001 ) compared with those who have consolidation .", "Evidence Elements": {"Participant": [{"term": "vasopressor at admission", "negation": "affirmed", "UMLS": {}, "start": 133, "end": 157}, {"term": "ground glass pattern", "negation": "affirmed", "UMLS": {}, "start": 297, "end": 317}], "Intervention": [{"term": "Dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 70}, {"term": "TCZ", "negation": "affirmed", "UMLS": {}, "start": 91, "end": 94}, {"term": "non-invasive ventilation", "negation": "affirmed", "UMLS": {}, "start": 187, "end": 211}, {"term": "mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 236, "end": 258}], "Outcome": [{"term": "survival", "negation": "affirmed", "UMLS": {}, "start": 13, "end": 21}], "Observation": [{"term": "better", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 44}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Cox regression analysis showed that , TCZ therapy ( HR = 2.162 , 95 % CI , 1.144-4.087 , P < 0.0001 ) compared with Dexamethasone group , higher neutrophil / Lymphocyte ratio ( HR = 2.40 , CI , 1.351-4.185 , P = 0.003 ) , lower PaO2 / FiO2 , 2 days after treatment , ( HR = 1.147 , 95 % CI , 1.002-1.624 , P < 0.0001 ) independently predicted higher probability of mortality .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "TCZ", "negation": "affirmed", "UMLS": {}, "start": 38, "end": 41}, {"term": "Dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 129}], "Outcome": [{"term": "Lymphocyte ratio", "negation": "affirmed", "UMLS": {}, "start": 158, "end": 174}, {"term": "FiO2", "negation": "affirmed", "UMLS": {}, "start": 235, "end": 239}], "Observation": [{"term": "higher", "negation": "affirmed", "UMLS": {}, "start": 138, "end": 144}, {"term": "lower", "negation": "affirmed", "UMLS": {}, "start": 222, "end": 227}], "Count": []}, "Evidence Propositions": [{"Intervention": ["TCZ", "Dexamethasone"], "Observation": "higher", "Outcome": "Lymphocyte ratio", "Count": ""}, {"Intervention": ["TCZ", "Dexamethasone"], "Observation": "lower", "Outcome": "FiO2", "Count": ""}]}, {"Section": "UNKNOWN", "Text": "Dexamethasone showed better survival in severe COVID-19 compared to TCZ .", "Evidence Elements": {"Participant": [{"term": "severe COVID-19", "negation": "affirmed", "UMLS": {}, "start": 40, "end": 55}], "Intervention": [{"term": "Dexamethasone", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 13}, {"term": "TCZ", "negation": "affirmed", "UMLS": {}, "start": 68, "end": 71}], "Outcome": [{"term": "survival", "negation": "affirmed", "UMLS": {}, "start": 28, "end": 36}], "Observation": [{"term": "better", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 27}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Considering the risk factors mentioned here is crucial when dealing with severe COVID-19 cases .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Clinical trial registration No clinicalTrials.gov : Nal protocol approved by Hospital Authorities , for data collection and for participation in CT04519385 ( 19 / 08 / 2020 ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}